Literature DB >> 9737666

Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells.

J Nasu1, M Mizuno, T Uesu, K Takeuchi, T Inaba, S Ohya, M Kawada, K Shimo, H Okada, T Fujita, T Tsuji.   

Abstract

Expression of DAF (CD55) is enhanced on colonic epithelial cells of patients with ulcerative colitis (UC), and stool DAF concentrations are increased in patients with active disease. Cytokines are known to modulate DAF expression in various human cells, and lesions of UC reveal altered profiles of cytokine production. In this study, we evaluate the effects of various cytokines, IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, and interferon-gamma (IFN-gamma), on the synthesis and kinetics of DAF protein in HT-29 human intestinal epithelial cells. Using flow cytometry and an ELISA, we found that HT-29 cells constitutively express DAF on the cell surface and spontaneously release DAF into the culture supernatant under standard culture conditions. When the culture supernatant was centrifuged at 100000g, nearly a half of DAF was precipitated, indicating that one half of the released DAF was present as a membrane-bound form and the other half as a soluble form. Analysis of the culture supernatant of biotin surface-labelled HT-29 cells suggested that the soluble form DAF was derived by secretion from within the cell or by cleavage from the cell surface. Among the cytokines, IL-4 markedly, and IL-1beta moderately, enhanced the expression and the release of DAF. Actinomycin D, cycloheximide, and brefeldin A inhibited the increase in DAF release induced by IL-4 and IL-1beta stimulation. These results suggest that DAF is released from intestinal epithelial cells in response to cytokine stimulation and that IL-4 and IL-1beta are possible cytokines involved in DAF release into the colonic lumen of patients with UC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737666      PMCID: PMC1905071          DOI: 10.1046/j.1365-2249.1998.00660.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer.

Authors:  M Mizuno; M Nakagawa; T Uesu; H Inoue; T Inaba; T Ueki; J Nasu; H Okada; T Fujita; T Tsuji
Journal:  Gastroenterology       Date:  1995-09       Impact factor: 22.682

3.  Human glomerular epithelial cells synthesize and secrete the third component of complement.

Authors:  A Moutabarrik; I Nakanishi; M Matsumoto; D Zaid; T Seya
Journal:  Nephron       Date:  1995       Impact factor: 2.847

4.  Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.

Authors:  L Bjørge; T S Jensen; R Matre
Journal:  Cancer Immunol Immunother       Date:  1996-03       Impact factor: 6.968

5.  Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC).

Authors:  T Ueki; M Mizuno; T Uesu; T Kiso; J Nasu; T Inaba; Y Kihara; Y Matsuoka; H Okada; T Fujita; T Tsuji
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

6.  Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface.

Authors:  S Tsuji; K Kaji; S Nagasawa
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

7.  Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC).

Authors:  T Inaba; M Mizuno; S Ohya; M Kawada; T Uesu; J Nasu; K Takeuchi; M Nakagawa; H Okada; T Fujita; T Tsuji
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

8.  Decreased mucosal interleukin-4 (IL-4) production in gut inflammation.

Authors:  R Karttunnen; E J Breese; J A Walker-Smith; T T MacDonald
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

9.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

10.  Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis.

Authors:  T Uesu; M Mizuno; H Inoue; J Tomoda; T Tsuji
Journal:  Lab Invest       Date:  1995-05       Impact factor: 5.662

View more
  14 in total

1.  Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.

Authors:  O B Spiller; O Criado-García; S Rodríguez De Córdoba; B P Morgan
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.

Authors:  Roma Pahwa; Uma Kumar; Nibhriti Das
Journal:  Mol Cell Biochem       Date:  2016-02-23       Impact factor: 3.396

Review 3.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 4.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

5.  Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor.

Authors:  Mary E W Collier; Camille Ettelaie
Journal:  J Biol Chem       Date:  2011-02-10       Impact factor: 5.157

6.  Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis.

Authors:  P F Halloran; M Afrouzian; V Ramassar; J Urmson; L F Zhu; L M Helms; K Solez; N M Kneteman
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

7.  Role of transcription factor Sp1 and RNA binding protein HuR in the downregulation of Dr+ Escherichia coli receptor protein decay accelerating factor (DAF or CD55) by nitric oxide.

Authors:  Manu Banadakoppa; Daniel Liebenthal; David E Nowak; Petri Urvil; Uma Yallampalli; Gerald M Wilson; Aparna Kishor; Chandra Yallampalli
Journal:  FEBS J       Date:  2013-01-02       Impact factor: 5.542

8.  Afa/Dr diffusely adhering Escherichia coli infection in T84 cell monolayers induces increased neutrophil transepithelial migration, which in turn promotes cytokine-dependent upregulation of decay-accelerating factor (CD55), the receptor for Afa/Dr adhesins.

Authors:  Fréderic Bétis; Patrick Brest; Véronique Hofman; Julie Guignot; Imad Kansau; Bernard Rossi; Alain Servin; Paul Hofman
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 9.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  Triggering of the dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial fibroblasts.

Authors:  Olga N Karpus; Kirstin M Heutinck; Paul J M Wijnker; Paul P Tak; Jörg Hamann
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.